

Contents

Series Editors' Preface *xiii*

Preface *xv*

1	Introduction	1
	<i>John Schneekloth Jr. and Martin Pettersson</i>	
	References	4
2	RNA Structure Probing, Dynamics, and Folding	7
	<i>Danny Incarnato</i>	
2.1	Introduction	7
2.1.1	Relevance of RNA Structure in Disease	8
2.1.2	Challenges in Studying RNA Structures	8
2.2	Experimentally Guided RNA Structure Modeling	9
2.2.1	Structural Interrogation of RNA Nucleotides via Chemical Probing	10
2.2.1.1	Limits of RNA Chemical Probing	12
2.2.2	Direct Mapping of RNA–RNA Interactions	14
2.2.2.1	Limits of RNA–RNA Interaction Mapping	16
2.2.3	Mapping Spatially Proximal Nucleotides in RNA molecules	17
2.2.3.1	Limits of Methods for Spatial Proximity Mapping	17
2.3	Dealing with RNA Structure Heterogeneity	19
2.4	Querying RNA–Small Molecule Interactions with Chemical Probing	22
2.5	Conclusions and Future Prospects	22
	References	23
3	High-Resolution Structures of RNA	29
	<i>Lukas Braun, Zahra Alirezaeizanjani, Roberta Tesch, and Hamed Kooshapur</i>	
3.1	Introduction	29
3.2	X-Ray Crystallography	31
3.3	NMR Spectroscopy	34
3.4	Cryo-EM	37
3.5	3D Structure Prediction and Integrative Approaches	39
3.6	Conclusions	43
	Acknowledgments	43
	Conflicts of Interest	43
	References	43

4 Screening and Lead Generation Techniques for RNA Binders 49

Gary Frey, Emily Garcia Segal, and Neil Lajkiewicz

- 4.1 Knowledge-Based Versus Agnostic Screening 49
- 4.2 Virtual Screening 50
- 4.3 Screening Methods 51
 - 4.3.1 High-Throughput Screening (HTS) 51
 - 4.3.1.1 Mass Spectrometry 51
 - 4.3.1.2 HTS of RNA Using Direct MS Approaches 52
 - 4.3.1.3 HTS of RNA Using Indirect MS Approaches 54
 - 4.3.1.4 DNA-Encoded Libraries (DELs) 56
 - 4.3.1.5 Microarray Screening 57
 - 4.3.1.6 Fragment-Based Drug Discovery 58
 - 4.3.1.7 Phage Display 63
 - 4.3.2 Orthogonal Methods 63
 - 4.3.2.1 Surface Plasmon Resonance 63
 - 4.3.2.2 Fluorescence-Based Assays 66
 - 4.3.2.3 Microscale Thermophoresis (MST) 70
 - 4.3.2.4 Isothermal Titration Calorimetry (ITC) 70
- 4.4 Binding Site Identification/Target Engagement 72
 - 4.4.1 Covalent Methods 72
 - 4.4.2 Competition with an Antisense Oligonucleotide (ASO) 74
- 4.5 Defining SAR and Functional Assays 75
 - 4.5.1 Functional Assays 75
 - 4.5.2 Phenotypic Screens 76
- 4.6 Identifying a Lead Series 76
 - 4.6.1 Hit Optimization 77
 - 4.6.2 Risdiplam Hit-to-Lead 78
 - 4.6.3 Branaplam Lead Generation 79
 - 4.6.4 Zotatfin Lead Generation 80
- 4.7 Concluding Thoughts and Outlook 80
 - Acknowledgments 81
 - References 81

5 Chemical Matter That Binds RNA 93

Emily G. Swanson Hay, Zhengguo Cai, and Amanda E. Hargrove

- 5.1 Introduction 93
- 5.2 Natural Ligands 94
 - 5.2.1 Aminoglycosides 94
 - 5.2.2 Tetracyclines 95
 - 5.2.3 Macrolides 96
 - 5.2.4 Native Riboswitch Ligands 96
- 5.3 Commercial Ligands 97
 - 5.3.1 Industrial Libraries 98
 - 5.3.2 Academic Libraries 98

5.4	Synthetic Ligands	99
5.4.1	Benzimidazoles and Purines	100
5.4.2	Naphthalenes, Quinolines, and Quinazolines	101
5.4.3	Oxazolidinones	102
5.4.4	Amilorides	102
5.4.5	Diphenyl Furan	103
5.4.6	Multivalent Ligands	103
5.5	Computational Tools for the Exploration of Chemical Space	103
5.5.1	Similarity Searches and Principal Component Analysis	104
5.5.2	Additional Machine-Learning Tools	105
5.5.3	Structure-Based Ligand Design	106
5.6	Case Studies in Examining and Expanding RNA-Targeted Chemical Space	106
5.6.1	Using QSAR to Probe RNA-Targeting Small-Molecule Properties	107
5.6.2	Evaluating the Chemical Space of Natural, Synthetic, and Commercial Ligands	108
5.7	Conclusions and Outlook	111
	Acknowledgments	111
	References	111
6	MicroRNAs as Targets for Small-Molecule Binders	119
	<i>Maria Duca</i>	
6.1	Introduction	119
6.2	MicroRNAs	121
6.3	MicroRNAs Biogenesis	122
6.4	Targeting MicroRNAs with Small-Molecule RNA Binders	123
6.4.1	Induction of miRNAs Expression: Tackling the Decrease of Tumor Suppressor miRNAs	124
6.4.2	Inhibition of miRNAs Production: Pre- and Pri-miRNA Binders	125
6.4.2.1	Discovery of miRNAs Inhibitors by Intracellular Assays	125
6.4.2.2	Target-Based <i>In Vitro</i> Assays	127
6.4.2.3	Design of Specific Ligands of Pre- and Pri-miRNAs	131
6.4.2.4	Fragment-Based Drug Design	138
6.4.2.5	DNA-Encoded Libraries (DELs)	139
6.5	Inhibition of RNA-Protein Interactions in miRNAs Pathways	140
6.6	Adding Cleavage Properties to miRNAs Interfering Agents	142
6.7	Conclusions	144
	References	144
7	Pre-mRNA Splicing Modulation	151
	<i>Scott J. Barraza and Matthew G. Woll</i>	
7.1	Introduction	151
7.2	Overview of Splicing Biology	152
7.2.1	The Spliceosome	152
7.2.2	Classes of Alternative Splicing	154

7.3	Pharmacological Mechanisms of Splicing Modulation	155
7.3.1	<i>Cis</i> - and <i>Trans</i> -Regulatory Elements (Splicing Factors)	155
7.3.1.1	Stabilization of <i>Cis</i> -Regulatory Elements	156
7.3.1.2	Destabilization of <i>Cis</i> -Regulatory Elements	158
7.3.1.3	Inhibition of <i>Cis</i> -Regulatory RNA–Protein Interactions	158
7.3.1.4	Inhibition of <i>Trans</i> -Regulatory Elements	160
7.3.1.5	Degradation of <i>Trans</i> -Regulatory Elements	161
7.3.1.6	Inhibition of <i>Trans</i> -Regulatory Element Protein–Protein Interactions (PPIs)	162
7.3.1.7	Stabilization of <i>Trans</i> -Regulatory Element RNA–Protein Interactions (RPIs)	165
7.3.2	Kinases and Phosphatases	165
7.3.2.1	Challenges in Targeting Kinases	167
7.3.2.2	Inhibition of Kinases	168
7.3.2.3	Activation and Degradation of Kinases	168
7.3.2.4	Inhibition and Activation of Protein Phosphatases	169
7.3.3	Epigenetic Writers and Erasers	172
7.3.3.1	Inhibition of Epigenetic Writers	172
7.3.4	RNA Helicases	174
7.3.5	Drugging the Spliceosome	175
7.3.5.1	Inhibition of U2 snRNP Recognition of the 3′-Splice Site	176
7.3.5.2	E7107	176
7.3.5.3	H3B-8800	177
7.3.5.4	Stabilizers of U1 snRNP Recognition of the 5′-Splice Site	180
7.3.5.5	Introduction to Spinal Muscular Atrophy (SMA)	180
7.3.5.6	Risdiplam (Evrysdi®)	183
7.4	Future Outlook	186
	References	188
8	Prospects for Riboswitches in Drug Development	203
	<i>Michael G. Mohsen and Ronald R. Breaker</i>	
8.1	Introduction	203
8.1.1	The Known Landscape of Riboswitches	203
8.1.2	Riboswitches in Drug Development	203
8.1.3	The Need for Novel Antibiotics	205
8.2	Riboswitches as Drug Targets	207
8.2.1	Why Target Riboswitches?	207
8.2.2	Features of a Druggable Riboswitch	208
8.2.3	Riboswitch-Targeted Drugs	208
8.2.3.1	Small Molecules Targeting FMN Riboswitches	208
8.2.3.2	Other Riboswitches Targeted in Proof-of-Principle Demonstrations	209
8.2.4	Barriers and Future Developments	210
8.3	Riboswitches as Tools for Antibiotic Drug Development	210
8.3.1	Riboswitches as Biosensors	210
8.3.2	A Riboswitch-Based Fluoride Sensor Illuminates Agonists of Fluoride Toxicity	211

8.3.3	A Riboswitch-Based ZTP Sensor Identifies Inhibitors of Folate Biosynthesis	211
8.3.4	A Riboswitch-Based SAH Sensor Reveals an Inhibitor of SAH Nucleosidase	212
8.3.5	Barriers and Future Developments	213
8.4	Application of Riboswitches in Gene Therapy	213
8.4.1	Considerations for Designer Riboswitches	213
8.4.2	Eukaryotic Expression Platforms	214
8.4.3	Barriers and Future Developments	216
8.5	Concluding Remarks	217
	Acknowledgment	218
	References	218
9	Small Molecules That Degrade RNA	227
	<i>Noah A. Springer, Samantha M. Meyer, Amirhossein Taghavi, Jessica L. Childs-Disney, and Matthew D. Disney</i>	
9.1	Antisense Oligonucleotide Degraders	227
9.2	Small-Molecule Direct Degraders	228
9.2.1	<i>N</i> -Hydroxypyridine-2(1 <i>H</i>)-thione (<i>N</i> -HPT) Conjugates	229
9.2.2	Bleomycin	229
9.2.3	Bleomycin Conjugates	231
9.2.3.1	Bleomycin Degraders Targeting the r(CUG) Repeat Expansion That Causes DM1	231
9.2.3.2	Bleomycin Degraders Targeting r(CCUG) Repeat Expansion that Causes DM2	233
9.2.3.3	Bleomycin Degraders Targeting Oncogenic Precursor microRNAs	233
9.2.3.4	Conclusions and Outlook for Bleomycin-Based Direct Degraders	234
9.3	Ribonuclease Targeting Chimeras (RiboTACs)	235
9.3.1	RNase L is an Endogenous Endoribonuclease That Functions as Part of the Innate Immune Response	236
9.3.2	First-Generation RiboTACs Targeting Oncogenic miRNAs	236
9.3.3	Small-Molecule-Based RiboTACs	239
9.3.4	Comparison of Bleomycin-Based Direct Degraders and RiboTACs	242
9.3.5	Discovery of Additional Small-Molecule RNase L Activators	242
9.3.6	Conclusions and Outlook for RiboTACs	243
9.4	Summary and Outlook for Small-Molecule RNA Degraders	244
	References	246
10	Approaches to the Identification of Molecules Altering Programmed Ribosomal Frameshifting in Viruses	253
	<i>Elinore A. VanGraafeiland, Diego M. Arévalo, and Benjamin L. Miller</i>	
10.1	Introduction	253
10.2	Mechanisms of Frameshifting	256
10.3	Targeting Frameshifting in HIV	257
10.4	Targeting Frameshifting in SARS-CoV-1 and SARS-CoV-2	263
10.5	Conclusions	274
	References	274

11	RNA–Protein Interactions: A New Approach for Drugging RNA Biology	281
	<i>Dalia M. Soueid and Amanda L. Garner</i>	
11.1	Molecular Basis of RNA–Protein Interactions	282
11.1.1	RNA Recognition Motifs (RRMs)	282
11.1.2	Double-Stranded RNA-Binding Domains (dsRBD)	286
11.1.3	Zinc Finger (ZnF) Domains	287
11.1.4	K Homology (KH) Domains	289
11.1.5	Other RBDs	290
11.2	Regulation and Dysregulation of RNA–Protein Interactions	290
11.2.1	Poor Quality Control Leads to Over- and Underproduction of RBPs	292
11.2.2	RBPs Become Out of Control, mRNA Processing Gets a Makeover (and Hates It)	294
11.2.3	RBP Shuttling of mRNA Becomes Askew	294
11.2.4	The RBP is Lost and Wreaks Havoc on the Cell	295
11.2.5	RBPs Dictate Which mRNAs are Translated, Favoring their Toxic Friends	295
11.2.6	RBPs and RNA Become Very Clique-y, Form Their Own Complex and Cause Stress to the Rest of the Cell	296
11.3	Experimental Methods to Detect and Screen for Small Molecules that Modulate RNA–Protein Interactions	297
11.3.1	<i>In vitro</i> Fluorescence-Based Assays	297
11.3.2	<i>In vitro</i> Chemiluminescence-Based Assays	297
11.3.2.1	Cell-Based RPI Detection Assays	300
11.3.3	Cell-Based RNA–Protein Interaction Screening	301
11.4	Closing Remarks	302
	References	303
12	Drugging the Epitranscriptome	321
	<i>Tanner W. Eggert and Ralph E. Kleiner</i>	
12.1	Introduction	321
12.2	Modifications on mRNA: <i>N</i> ⁶ -Methyladenosine, Pseudouridine, and Inosine	325
12.2.1	<i>N</i> ⁶ -Methyladenosine (m ⁶ A)	325
12.2.2	Pseudouridine (Ψ)	327
12.2.3	Inosine (I)	328
12.3	Modifications on tRNA and rRNA	330
12.3.1	tRNA Modifications	330
12.3.2	rRNA Modifications	334
12.4	Concluding Remarks	335
	References	336

13	Outlook	355
	<i>Christopher R. Fullenkamp, Xiao Liang, Martin Pettersson, and John Schneekloth Jr.</i>	
13.1	Introduction	355
13.2	Target Selection: Identification of the Most Promising RNA Intervention Points	357
13.3	Development of Robust Biophysical Methods, Alternative Strategies for Target Engagement, and Accurate and Reliable Functional Models	358
13.3.1	Biophysical Methods for Interrogating Small Molecule–RNA Interactions	358
13.3.2	Cellular Target Engagement Methods	360
13.3.3	Unique Challenges Faced in the Development of Functional Assays for Studying Small Molecule–RNA Interactions	364
13.4	Acquisition of High-Resolution RNA and RNA–Ligand Structures is Needed to Enable the Development and Validation of Computational Tools for RNA–Small Molecule Therapeutic Discovery	367
13.4.1	RNA Structure Prediction	367
13.4.2	Computational Tools for Hit Optimization	369
13.4.3	Implementation of Molecular Dynamics Simulations, Machine Learning, and AI Tools to Interrogate RNA–Small Molecule Interactions	371
13.5	Deposition of Small Molecule–RNA Interaction Data with Rigorous Experimental Protocols and Controls is Needed	373
13.6	Outlook: The Future of Small Molecule-Based RNA Therapeutics is Bright	375
	References	376
	Index	385